Evaluation of the effect of Silybum marianum on endometriosis
Phase 3
- Conditions
- Endometriosis.N80.1Endometriosis of ovary
- Registration Number
- IRCT20200925048836N4
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Female
- Target Recruitment
- 60
Inclusion Criteria
Endometriosis recorded by transvaginal ultrasound or transrectal ultrasound by a gynecologist
No history of endometriosis surgery
Without any chronic inflammatory disease and chronic medical conditions such as cancer, diabetes, cardiovascular disease and rheumatic disease
Age less than 45 years old
The patient is without surgical indication
Exclusion Criteria
Breast Cancer
probability of side effects such as severe nausea, vomiting, diarrhea or gastrointestinal symptoms
Previous endometriosis surgery
Cervical or ovarian cancer
Uterine fibroid
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method AMH level. Timepoint: Six months after starting the medication. Method of measurement: Hormone kits (Diazist).;Endometrioma size. Timepoint: At the beginning of the study and 6 months later. Method of measurement: Transvaginal or transrectal ultrasonography.
- Secondary Outcome Measures
Name Time Method